Which company could become the Chinese Pfizer? Here are analysts’ top picks
A handful of Chinese biotechnology companies are expected to bring medications to consumers in Europe and the US under their own brand names within the next 10 to 15 years, according to policy and industry analysts. Amid China’s early-stage drug outlicensing boom, discussions have arisen among investor and analyst circles as to when – and which – Chinese biotechnology companies will start selling their own drugs internationally. Outlicensing agreements typically refer to a co
Chinese biotechnology firms are poised to enter European and US markets with their own branded medications within the next decade to fifteen years, according to industry analysts. This development follows a significant increase in early-stage drug outlicensing deals originating from China. Analysts and investors are actively discussing which domestic companies will be the first to achieve this international commercialization milestone.
The trend indicates a growing maturity and global ambition within China's biopharmaceutical sector, moving beyond research collaborations to direct market presence.
This shift could significantly alter the global pharmaceutical landscape, introducing new competitors and potentially increasing access to innovative treatments worldwide.
📌 Kaynak
Bu özet SCMP China kaynağından otomatik derlenmiştir. Tamamı için orijinal habere gidin.
Orijinal haberi oku →